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ABSTRACT Although alterations in DNA methylation
patterns have been associated with specific diseases and
environmental exposures, the mediators and signaling
pathways that direct these changes remain understud-
ied. The bioactive lipid mediator prostaglandin E2
(PGE2) has been shown to exert a myriad of effects on
cell survival, proliferation, and differentiation. Here,
we report that PGE2 also signals to increase global DNA
methylation and DNA methylation machinery in fibro-
blasts. HumanMethylation27 BeadChip array analysis
of primary fetal (IMR-90) and adult lung fibroblasts
identified multiple genes that were hypermethylated in
response to PGE2. PGE2, compared with nontreated
controls, increased expression and activity (EC5010
7
M) of one specific isoform of DNA methyltransferase,
DNMT3a. Silencing of DNMT3a negated the ability of
PGE2 to increase DNMT activity. The increase in
DNMT3a expression was mediated by PGE2 signaling
via its E prostanoid 2 receptor and the second messen-
ger cAMP. PGE2, compared with the untreated control,
increased the expression and activity of Sp1 and Sp3
(EC50310
7 M), transcription factors known to in-
crease DNMT3a expression, and inhibition of these
transcription factors abrogated the PGE2 increase of
DNMT3a expression. These findings were specific to
fibroblasts, as PGE2 decreased DNMT1 and DNMT3a
expression in RAW macrophages. Taken together,
these findings establish that DNA methylation is regu-
lated by a ubiquitous bioactive endogenous mediator.
Given that PGE2 biosynthesis is modulated by environ-
mental toxins, various disease states, and commonly
used pharmacological agents, these findings uncover a
novel mechanism by which alterations in DNA methyl-
ation patterns may arise in association with disease and
certain environmental exposures.—Huang, S. K.,
Scruggs, A. M., Donaghy, J., McEachin, R. C., Fisher,
A. S., Richardson, B. C., Peters-Golden, M. Prostaglan-
din E2 increases fibroblast gene-specific and global
DNA methylation via increased DNA methyltransferase
expression. FASEB J. 26, 3703–3714 (2012). www.fasebj.
org
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The DNA methylation profile of cells is highly plastic
and susceptible to alteration by endogenous mediators
and exogenous environmental factors (1, 2); however,
the mechanisms by which such factors direct specific
changes in the methylation pattern are, in many in-
stances, poorly understood. Both normal cellular dif-
ferentiation (3) and pathological processes such as
tumorigenesis (4, 5), inflammation (6, 7), and fibrosis
(8, 9) are associated with changes in the DNA methyl-
ation profile. Locally produced lipid mediators are
important endogenous participants in numerous ho-
meostatic functions and in disease pathogenesis, but it
is not known whether they can alter the DNA methyl-
ation pattern in cells.
Prostaglandin E2 (PGE2) is one of the most ubiqui-
tous and important endogenous lipid mediators, and it
exerts pleiotropic actions that can vary depending on
the context, the tissue environment, and the cell type
(10). It is produced constitutively in nearly all tissues,
but its synthesis is highly regulated, being increased
with the induction of cyclooxygenase (COX) and PGE
synthase enzymes in response to microbes, cytokines,
hormones, and growth factors and decreased in re-
sponse to glucocorticoids. Although it has long been
recognized during states of inflammation to cause
fever, pain, and local tissue edema, PGE2 can also act
on epithelial, mesenchymal, and immune cells to influ-
ence cellular proliferation (11), differentiation (12),
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and function (11, 13, 14) and on cancer cells to
promote tumorigenesis (15). PGE2 achieves this diver-
sity of function by its ability to ligate 4 different
G-protein-coupled receptors, E prostanoid (EP) 1–4,
which are coupled to distinct G proteins and signal via
alterations in specific second messengers (e.g., cAMP or
Ca2) (16).
In view of the ability of PGE2 to regulate a myriad of
fundamental cellular functions in which DNA methyl-
ation has been implicated, we sought to determine
whether PGE2 is able to directly influence the DNA
methylation pattern in cells. In lung fibroblasts, we and
others have previously shown that PGE2 inhibits fibro-
blast to myofibroblast differentiation (12), fibroblast
proliferation, and fibroblast production of matrix pro-
teins (11, 17). In this study, we show that PGE2 induces
global and gene-specific increases in DNA methylation
in lung fibroblasts. This increase in DNA methylation
was due to increased expression and activity of the
specific DNA methyltransferase (DNMT) 3a. Although
the expression of 15-lipoxygenase (18), COX-2 (19),
and E prostanoid receptors (9) is known to be regu-
lated by DNA methylation, these findings demonstrate
the converse relationship, namely, that PGE2 is capable
of increasing global and gene-specific DNAmethylation
through increased expression and activation of a spe-
cific de novo DNMT.
MATERIALS AND METHODS
Cell culture
Primary fetal (IMR-90) and adult (CCL-210, CCL-204, and
CCL-209) lung fibroblasts were purchased from American
Type Culture Collection (Manassas, VA, USA) and were
cultured in Dulbecco’s modified Eagle medium (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (HyClone, Logan, UT, USA) and 1% penicillin/
streptomycin. Cells from the murine monocyte-macrophage
leukemic cell line, RAW 264.7, were cultured in Roswell Park
Memorial Institute medium. All experiments were performed
on cells at passages 5–9. Cells were plated unless otherwise
noted at 5  105 cells/well in 6-well plates, serum starved
overnight, and treated with the following reagents: PGE2
(109 to 106 M), the prostacyclin [prostaglandin I2 (PGI2)]
analogs iloprost (1 M) and treprostinil (1 M), PGD2 (1
M), the thromboxane A2 analog U-4419 (1 M), and the
EP2 agonist butaprost free acid (500 nM) (all from Cayman
Chemical, Ann Arbor, MI, USA); aspirin (200 M), the
DNA-damaging agent temozolomide (100 and 250 M), and
actinomycin D (2.5 g/ml) (all from Sigma-Aldrich, St.
Louis, MO, USA); IL-1 (10 ng/ml; BD Biosciences, Sparks,
MD, USA); the EP3 agonist ONO-AE3-248 (100 nM), the EP4
agonist ONO-AE1-329 (100 nM), and the EP4 antagonist
ONO-AE3-208 (100 nM) (kind gifts from Ono Pharmaceuti-
cals, Osaka, Japan); the adenyl cyclase activator forskolin (100
M; EMD Chemicals, San Diego, CA, USA); the EP2 antago-
nist AH6809 (10 M; Enzo Life Sciences, Farmingdale, NY,
USA); and the Sp1/Sp3 inhibitor mithramycin (25–50 nM;
Tocris Bioscience, Bristol, UK). For small interfering RNA
(siRNA) experiments, cells were cultured to 30–50% conflu-
ence and transfected with siRNAs against DNMT1, DNMT 3a,
and DNMT 3b (Qiagen, Valencia, CA, USA) using Lipo-
fectamine LTX (Invitrogen) for 48 h in OptiMEM medium
(Invitrogen) before being treated with or without PGE2.
Specificity of the siRNAs was confirmed by real-time RT-PCR
and has been reported previously (9).
Global and gene-specific DNA methylation
Genomic DNA was isolated from 1  106 cells using DNeasy
(Qiagen). Levels of global DNA methylation were assayed
using the MethylFlash Methylated DNA Quantification Kit
from Epigentek (Farmingdale, NY, USA) according to the
manufacturer’s protocol.
For gene- and site-specific analysis, 1 g of genomic DNA
was subject to bisulfite conversion using the EZ DNA Methyl-
ation Kit from Zymo Research (Irvine, CA, USA). Bisulfite-
converted DNA was analyzed for methylation at 27,578 CpG
sites using the HumanMethylation27 BeadChip array (Illu-
mina; San Diego, CA, USA) according to the manufacturer’s
protocol. Signal intensity from methylated and unmethylated
probes for all sites was scanned on the Illumina BeadArray
Reader and preprocessed using Illumina GenomeStudio soft-
ware. The methylation status of individual CpG sites was
verified by pyrosequencing. Bisulfite-modified DNA was am-
plified by PCR using biotin-labeled primers specific for the
IGFBP2 and MGMT promoter. The amplified product was
then mixed with sequence-specific primers and analyzed for
methylation at individual CpG sites using a Pyrosequencer
(Qiagen). IGFBP2 and MGMT amplification and sequencing-
specific primers were obtained from EpigenDx (Worcester,
MA, USA). Long interspersed element (LINE)-1 amplifica-
tion and sequencing primers were obtained from Qiagen.
DNMT activity assay
Cells (3106) were plated in 100-mm culture dishes and
treated with PGE2 for 48 h. Cells were scraped, and nuclear
fractions were collected using the Panomics Nuclear Extrac-
tion Kit (Affymetrix, Santa Clara, CA, USA). DNMT activity of
nuclear extracts was assayed according to the manufacturer’s
protocol using the DNMT Activity Assay (ActiveMotif, Carls-
bad, CA, USA).
Real-time RT-PCR
RNA was isolated from cells using TRIzol (Invitrogen), and
quantitative mRNA levels were assayed by real-time RT-PCR
using the Applied Biosystems 7300 Real-Time PCR System
(Applied Biosystems, Carlsbad, CA, USA). Primers for human
and murine DNMT1, DNMT3a, and DNMT3b and human
Sp1 and Sp3 were obtained from Applied Biosystems. Primer
and probes for human and murine -actin were used as
reported previously (11).
Immunoblotting
Cell lysates were collected in lysis buffer (PBS containing 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM
orthovanadate, and protease cocktail inhibitor), resolved by
SDS-PAGE, transferred to nitrocellulose membranes, and
immunoblotted using antibodies to the following: DNMT1 (2
g/ml; Imgenex, San Diego, CA, USA), DNMT3a (2 g/ml;
Abcam, Cambridge, MA), DNMT3b (4 g/ml; Abcam), O6-
methylguanine DNA methyltransferase (MGMT; 1:1000; Cell
Signaling Technology, Beverly, MA, USA), poly(ADP-ribose)
polymerase (PARP; 1:1000; Cell Signaling Technology), and
-tubulin (1:1000; Sigma-Aldrich). Bound primary antibodies
were visualized with appropriate secondary antibody conju-
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gated to horseradish peroxidase and developed with en-
hanced chemiluminescence reagent (GE Healthcare, Piscat-
away, NJ, USA). Densitometric analysis was performed on the
visualized bands using Scion Image software (U.S. National
Institutes of Health, Bethesda, MD, USA).
COMET assay
The COMET assay (Cell Biolabs, San Diego, CA, USA) was
used to measure DNA damage, as described previously (20).
Cells were pretreated with PGE2 (500 nM) for 48 h. Medium
was then removed, and cells were treated for 24 h with the
DNA-damaging agent temozolomide (100–250 M). Cells
were then collected, centrifuged, and resuspended in a 1:10
PBS-agarose mixture and placed on glass slides. The cells
were washed, permeabilized, and subjected to an electric
gradient of 1 V/ml of chamber length for 12 min as per the
manufacturer’s instructions. Nuclear material was stained and
visualized by fluorescent microscopy. The percentage of cells
that exhibited a comet tail and the length of the comet tail
were measured to quantitate the degree of DNA damage.
Sp1 activity assay
Nuclear extracts were isolated from cells as described above
and assayed for Sp1 activity according to the manufacturer’s
protocol using the Sp1 Transcription Factor Activity Assay Kit
(Affymetrix).
Data analysis
Data were analyzed on GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA, USA) using ANOVA or Student’s t
test, as appropriate, with P  0.05 defined as statistically
significant. Data are expressed as means 	 se. For the
HumanMethylation27 array data, signal intensities were cor-
rected for red/green color balance, adjusted for background
signal, and normalized across the set of arrays. M values were
calculated as the log2 ratio of the intensities of the methylated
probe vs. unmethylated probe, as described by Du et al. (21).
M values were then compared between groups treated with vs.
without PGE2, and statistically significant differences were
identified using the limma algorithm in the Bioconductor
suite (ref. 22; http://www.bioconductor.org). Significant dif-
ferences in M values were defined by both P  0.05 and a fold
change of 
1.5 or 2 as noted. Enrichment analysis was
performed using ConceptGen (http://conceptgen.ncibi.org)
with Q  0.05 defined as statistically significant.
RESULTS
PGE2 increases global and gene-specific DNA
methylation in fibroblasts
Using the primary fetal lung fibroblast cell line IMR-90,
we first determined the effect of PGE2 on global DNA
methylation. Cells were treated with PGE2 (10
9 to
106 M) for 48 h and assayed for total methylated DNA
using an ELISA-based assay. Although PGE2 did not
affect levels of global methylation at 24 h (data not
shown), it dose dependently increased global DNA
methylation by up to 2-fold after 48 h of treatment
(Fig. 1A). The increase in global DNA methylation
elicited by PGE2 was also observed in primary adult
lung fibroblasts (Fig. 1B).
In the mammalian genome, DNA methylation is
most abundant along centromeric and interspersing
noncoding intergenic regions (23). To determine
whether the observed increase in global methylation
reflects a change in methylation along these noncoding
regions, we performed bisulfite sequencing to assay the
methylation status of LINE-1. We did not observe a
significant change in LINE-1 methylation in either
IMR-90 or adult normal cells treated with PGE2 (Sup-
plemental Fig. S1).
We next sought to determine whether the increase in
global DNA methylation elicited by PGE2 reflected an
increase in methylation of specific gene promoters. We
used the Illumina HumanMethylation27 BeadChip ar-
ray to survey the methylation status of 27,578 CpG sites
(most of which are located within the promoters of
genes and many of which are within CpG islands) in
IMR-90 and adult lung fibroblasts treated with or
without PGE2 for 48 h (n3 for each cell type).
Selecting those CpG sites that exhibited a significant
increase or decrease in methylation (P0.05 and a
2-fold change in M value), we identified 18 genes
differentially methylated by PGE2 in IMR-90 cells
(Table 1). Of those, more than two-thirds showed an
increase rather than a decrease in methylation. Using
the same criteria in adult cells, we identified 5 genes
that were hypermethylated and no genes that were
hypomethylated by PGE2 (Table 2).
To further explore the observed hypermethylation by
PGE2, we broadened our selection criteria from the
array to include genes that exhibited only an increase
in methylation (P0.05 but with a fold change 
1.5 in
M value). This selection yielded 52 genes whose meth-
ylation was increased by PGE2 in IMR-90 cells (Supple-
mental Table S1). Placing these results into biological
context, we used ConceptGen (24) to perform enrich-
ment analysis. ConceptGen combines annotations
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Figure 1. Effect of PGE2 on global DNA methylation. Primary
fetal lung fibroblasts (IMR-90; n3–5; A) and adult lung
fibroblasts (n5; B) were treated with or without PGE2 at the
indicated concentrations for 48 h, and global DNA methyl-
ation levels were assayed as described in Materials and Meth-
ods. All results are expressed as means 	 se. *P  0.05.
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found in gene ontology and gene pathway resources
with literature-derived MeSH annotations. ConceptGen
identified 3 literature-derived statistically significant
(Q0.05) concept groups—cyclin-dependent kinase
inhibitor p16, tumor suppressor proteins, and DNA
methylation—with annotations enriched for the hyper-
methylated genes identified from the array data
(Fig. 2A). Interestingly, the function of these enriched
groups is congruent with the previously described abil-
ity of PGE2 to inhibit fibroblast proliferation (11) and
fibroblast survival (25).
To independently verify the hypermethylation of
genes identified from the array, we performed bisulfite
sequencing of the IGFBP2 and the MGMT promoters.
These genes were chosen based on their fold change in
methylation by array analysis and the identification of
these genes by the aforementioned functional enrich-
ment analysis. We focused on 5 CpG loci within the
IGFBP2 promoter, including one that was identified by
the array and 4 adjacent sites. PGE2 treatment resulted
in an increase in methylation in all five sites assayed
(Fig. 2B), with the average degree of methylation at
these sites increasing from 6.7 to 13.1% (P0.05). We
also performed bisulfite sequencing of 22 CpG loci
within the MGMT promoter. The mean methylation of
all 22 loci increased from 17.3 to 21.5% (P0.05) with
PGE2 treatment, with a more marked increase in meth-
ylation observed in 8 particular CpG loci (Fig. 2C). To
determine whether the hypermethylation of the MGMT
promoter resulted in decreased protein expression, we
examined the expression of MGMT by immunoblot
analysis and observed that PGE2 dose dependently
decreased MGMT expression (Fig. 2D).
MGMT is a DNA repair enzyme up-regulated during
DNA damage, and its expression has been shown to
increase after injury with temozolomide (26). To deter-
mine the functional relevance of hypermethylation of
MGMT and diminished MGMT expression by PGE2, we
pretreated cells with or without PGE2 for 48 h. Medium
was then changed, and cells were subsequently treated
with temozolomide. Cells pretreated with PGE2 exhib-
ited increased susceptibility to DNA damage by temo-
zolomide, as shown in COMET assays (Fig. 2E), and to
cellular apoptosis, as shown by an increase in cleaved
PARP (Fig. 2F). These data are congruent with previous
studies that have shown that PGE2 increases fibroblast
susceptibility to apoptosis (25) and suggest the hyper-
methylation of MGMT may be partially responsible for
the decrease in cell survival.
PGE2 increases DNMT activity and gene expression
Given the observed increase in global and gene-specific
methylation by PGE2, we sought to determine whether
the increase in methylation was due to an increase in
nuclear activity of DNMTs, the enzymes responsible for
the addition of methyl groups to DNA. The nuclear
fractions of cells treated for 48 h with or without PGE2
TABLE 1. Genes with 
2- or 0.5-fold change in methylation after PGE2 treatment in IMR-90 cells
Gene ID Gene symbol Chromosome CPG map site Fold change P
64776 C11orf1 11 111255565 4.189 0.002
5253 PHF2 9 95378980 3.527 0.033
1028 CDKN1C 11 2862072 3.150 0.040
985 CDC2L2 1 1645098 3.041 0.005
55071 C9orf40 9 76757181 2.719 0.043
4097 MAFG 17 77478941 2.549 0.004
3485 IGFBP2 2 217206819 2.373 0.014
595 CCND1 11 69167000 2.226 0.032
8975 USP13 3 180853518 2.201 0.027
79006 METRN 16 705435 2.123 0.034
126789 PUSL1 1 1233923 2.072 0.047
29902 C12orf24 12 109391110 2.066 0.021
26524 LATS2 13 20533665 2.052 0.038
55693 JMJD2D 11 94346603 0.471 0.003
5649 RELN 7 103418455 0.447 0.020
23518 R3HDM1 2 136005195 0.444 0.019
51105 PHF20L1 8 133857529 0.408 0.020
8829 NRP1 10 33663793 0.336 0.039
TABLE 2. Genes with 
2- or 0.5-fold change in methylation after PGE2 treatment in adult fibroblasts
Gene ID Gene symbol Chromosome CpG map site Fold change P
8726 EED 11 85633629 12.740 0.001
79891 ZNF671 19 62930886 6.408 0.049
55693 JMJD2D 11 94346603 3.690 0.004
2300 FOXL1 16 85169514 2.612 0.000
3364 HUS1 7 47985966 2.196 0.011
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Figure 2. Genes hypermethylated by PGE2. A) Functional cluster analysis was performed on 52 genes identified as exhibiting a 1.5-fold
increase in M value methylation (P0.05) with PGE2 treatment in IMR-90 cells. Three functional clusters were identified (Q0.05), with
the genes associated with each cluster listed. B, C) Methylation status of CpG loci within the IGFBP2 (B) and MGMT (C) promoters, with
the location relative to the transcription start site indicated by numbers at bottom, was determined by bisulfite pyrosequencing in IMR-90
cells treated with PGE2 for 48 h. Mean methylation levels from 4 independent experiments at each of the indicated CpG loci is shown. D)
MGMT protein expression was assayed by immunoblot and quantitated by densitometric analysis with values normalized to -tubulin and
expressed relative to untreated cells (n4). Top panel shows a representative immunoblot. IMR-90 cells were pretreated with PGE2 (500
nM) for 48 h, washed, and subsequently treatedwith or without temozolomide (TMZ) for 24 h.E)DNAdamagewas assayed by theCOMET
assay, as described in Materials and Methods, and visualized by fluorescence microscopy. Representative images from 3 independent
experiments are shown. Arrowheads indicate representative cells with comet tails, which signify DNA damage. Graph quantifies the
percentage of cells that exhibited a comet tail and the mean length of comet tails. F) Apoptosis of cells was assayed by immunoblotting for
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were isolated and assayed for DNMT activity. PGE2 dose
dependently increased DNMT activity in IMR-90
(Fig. 3A) and primary adult lung fibroblasts (Fig. 3B).
In mammalian cells, 3 major DNMT isoforms,
DNMT1, DNMT3a, and DNMT3b, have been shown to
exhibit in vitro and in vivo methyltransferase activity
(27). DNMT1, by virtue of its preference for hemi-
methylated DNA over unmethylated DNA (28), is often
considered a maintenance methyltransferase whereas
DNMT3a and DNMT3b, by virtue of their lack of
preference between unmethylated and hemimethy-
lated DNA, have traditionally been regarded as de novo
methyltransferases (27). To determine whether the
increase in DNMT activity by PGE2 is associated with a
change in expression of specific DNMT isoforms, we
performed real-time RT-PCR and observed that 24-h
treatment with PGE2 dose dependently increased
DNMT1 and especially DNMT3a mRNA levels in both
IMR-90 (Fig. 3C) and adult lung fibroblasts (Fig. 3D).
The increase by PGE2 in DNMT3a mRNA at 24 h
corresponded to an increase in DNMT3a protein ex-
pression at 48 h, as assayed by immunoblot, in both
IMR-90 (Fig. 3E) and adult fibroblasts (Fig. 3F). There
was no change in DNMT1 protein expression despite
the increase in its mRNA.
To evaluate the contributions of each DNMT isoform
to enzyme activity, we pretreated IMR-90 cells with
control and DNMT isoform-specific siRNAs for 48 h
followed by PGE2 for an additional 48 h. The selective
ability of these isoform-specific siRNAs under the ex-
perimental conditions used to knock down expression
of their respective target DNMTs was reported previ-
ously (9). At baseline, silencing of DNMT1 and
DNMT3b, but not of DNMT3a, decreased basal DNMT
activity (Fig. 4A). The ability of PGE2 to increase DNMT
activity was preserved with control, DNMT1, and
DNMT3b siRNA treatment but was selectively abro-
gated with DNMT3a siRNA treatment (Fig. 4B). These
data suggest that although DNMT3a is not a significant
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Figure 4. Effect of silencing DNMT isoforms on DNMT
activity. IMR-90 cells were treated with control or isoform-
specific DNMT siRNA for 48 h and then were treated with or
without PGE2 (500 nM) for an additional 48 h before being
assayed for DNMT activity as described in Materials and
Methods. A) DNMT activity of cells treated with different
target siRNAs at baseline without PGE2 treatment, with rela-
tive activity normalized to control siRNA. B) DNMT activity of
cells treated with PGE2 (expressed as a fold change relative to
no PGE2). All results are expressed as means 	 se; n  3
*P  0.05 vs. control siRNA.
A
B D
C
  
*
**
**
*
3
2
1
0
4
5
  
  
DNMT3a
DNMT1
DNMT3b
 
*
*
*
*
**
 
3
2
1
0
DNMT3a
DNMT1
DNMT3b
PGE2 (M)
DNMT1
DNMT3a
DNMT3b
E F
 
*
*
0
1
2
3
4
DNMT3a
DNMT1
DNMT3b
0
0
1
2
3
4
DNMT3a
DNMT3b
DNMT1
*
*
*
10
20
30
40
0
*
Un
tre
ate
d
1.0
2.0
0.0
0.5
1.5
D
N
M
T 
pr
ot
ei
n 
ex
pr
es
sio
n
(re
lat
ive
 to
 α
-
tu
bu
lin
)
PGE2 (M)
10-9 10-8 10-7 10-60
PGE2 (M)
10-9 10-8 10-7 10-6
- 10-9 10-8 10-7 5  
x1
0-
7
10-6
α-tubulin
α-tubulin
α-tubulin
PGE2 (M)
DNMT1
DNMT3a
DNMT3b
- 10-9 10-8 10-7 5  
x1
0-
7
10-6
α-tubulin
α-tubulin
α-tubulin
0
PGE2 (M)
10-9 10-8 10-7 10-6
0
PGE2 (M)
10-9 10-8 10-7 10-6
0
PGE2 (M)
10-9 10-8 10-7 10-6
PG
E 2 
5x
10
-
7  M
D
N
M
T 
Ac
tiv
ity
(fo
ld
 c
ha
ng
e 
re
l t
o 
co
nt
ro
l)
D
N
M
T 
m
R
N
A 
le
ve
ls
(re
lat
ive
 to
 u
nt
re
at
ed
)
D
N
M
T 
pr
ot
ei
n 
ex
pr
es
sio
n
(re
lat
ive
 to
 α
-
tu
bu
lin
)
D
N
M
T 
Ac
tiv
ity
(O
D/
h/m
g p
rot
ein
)
D
N
M
T 
m
R
N
A 
le
ve
ls
(re
lat
ive
 to
 u
nt
re
at
ed
)
Figure 3. Effect of PGE2 on DNMT activity and expression. A,
B) IMR-90 cells (n4–6; A) and adult lung fibroblasts (n3;
B) were treated for 48 h with the indicated concentrations of
PGE2 and assayed for nuclear DNMT activity, as described in
Materials and Methods. C, D) DNMT1, DNMT3a, and
DNMT3b mRNA levels in IMR-90 fibroblasts (n6; C) and
adult lung fibroblasts (n4; D) treated for 24 h with the
indicated concentrations of PGE2 were assayed by quantita-
tive real-time RT-PCR. DNMT mRNA levels were normalized
to -actin and are expressed as fold change relative to no
PGE2-treatment controls. E, F) DNMT1, DNMT3a, and
DNMT3b protein expression in IMR-90 cells (n4; E) and
adult lung fibroblasts (n3; F) treated for 48 h with varying
concentrations of PGE2 were assayed by immunoblot analysis.
Top panels: representative immunoblots. Bottom panels: fold
change in expression based on mean densitometric analysis,
normalized to -tubulin. All results are expressed as means 	
se. *P  0.05.
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contributor to basal DNMT activity, the increase in
DNMT activity by PGE2 is predominantly mediated by
an increase in DNMT3a expression.
Endogenous levels of PGE2 regulate expression of
DNMT3a
Prostanoids are elaborated constitutively by fibroblasts,
and production can increase when expression of key
synthetic enzymes such as COX-2 is increased. To
determine whether endogenously generated prosta-
noids also modulate expression of DNMT isoforms, we
treated IMR-90 cells for 24 h with the COX inhibitor
aspirin and/or the cytokine IL-1, which potently in-
duces COX-2 expression, and assayed DNMT mRNA
levels. IL-1 significantly increased DNMT1 and
DNMT3a mRNA levels, and its effect was blocked by
concomitant treatment with aspirin (Fig. 5A). Aspirin
alone modestly but significantly decreased DNMT3a
expression. These findings suggest that increases and
decreases in endogenously synthesized prostanoids are
sufficient to modulate expression of DNMT3a.
Because prostanoids other than PGE2 can also be
produced from COX actions on arachidonic acid, we
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Figure 5. Role of endogenous prostanoids and specific PGE2 receptors in regulating DNMT expression. A) IMR-90 cells were
treated with or without aspirin (ASA, 200 M) and IL-1 (10 ng/ml) for 24 h and assayed for DNMT1, DNMT3a, and DNMT3b
mRNA levels by real-time RT-PCR, with values expressed relative to the no-treatment control. n  3. B) IMR-90 cells were treated
for 24 h with either PGE2 (500 nM), PGI2 analogs iloprost (1 M) or treprostinil (1 M), PGD2 (1 M), or thromboxane A2
(TxA2) analog U-4419 (1 M) and assayed for DNMT1, DNMT3a, and DNMT3b mRNA levels by real-time RT-PCR, with results
expressed as fold change relative to the no-treatment control. n  7. C) IMR-90 cells were treated with either PGE2 (500 nM),
the EP2 agonist butaprost free acid (500 nM), the EP3 agonist ONO-AE3-248 (100 nM), the EP4 agonist ONO-AE1-329 (100
nM), or the adenyl cyclase activator forskolin (100 M) for 24 h and assayed for DNMT1, DNMT3a, and DNMT3b mRNA levels
by real-time RT-PCR. Results are expressed as fold change relative to the untreated control. n  7. D) IMR-90 cells were
pretreated for 30 min in the presence or absence of an EP2 antagonist AH6809 (10 M) or the EP4 antagonist ONO-AE3-208
(100 nM) before treatment with PGE2 (500 nM) for 24 h. DNMT3a mRNA levels were assayed by real-time RT-PCR, with results
expressed as fold change relative to no PGE2 treatment. n  4. All results are expressed as means 	 se. *P  0.05 vs. untreated.
#P  0.05 for IL-1-treated with ASA vs. no ASA.
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compared the ability of PGE2 to modulate DNMT
expression with that of the PGI2 analogs iloprost and
treprostinil, PGD2, and the thromboxane A2 analog
U-4419. Among the prostanoids tested, only PGE2 was
able to increase DNMT3a mRNA levels (Fig. 5B) and
DNMT3a protein expression (as confirmed by immu-
noblot, data not shown). Because PGE2 is the predom-
inant IL-1-induced prostanoid synthesized by lung
fibroblasts (29), these data suggest that PGE2 is the
specific fibroblast-derived prostanoid mediating the
effect (Fig. 5A) of IL-1.
PGE2 increases DNMT3a expression via EP2-cAMP
signaling and increased expression of Sp1 and Sp3
PGE2 treatment resulted in an increase in DNMT3a
mRNA at 24 h, and an increase in DNMT3a protein
expression, nuclear DNMT activity, and global DNA
methylation levels at 48 h. To test whether a prolonged
exposure to PGE2 is necessary for the increase in
DNMT expression, we treated cells with PGE2 for only
1 h before removing the medium and replacing it with
PGE2-free medium (Supplemental Fig. S2). Cells ex-
posed to PGE2 for 1 h exhibited an increase in
DNMT3a mRNA levels at 24 h similar to that of cells in
which the medium was not removed, suggesting that
early PGE2 signaling events are sufficient to increase
DNMT3a expression.
PGE2 signals by ligating one of 4 G-protein-coupled
EP receptors (16). The EP2 and EP4 receptors signal
predominantly through Gs, leading to activation of
adenyl cyclase and increased production of the second
messenger cAMP. EP1 and EP3 are predominantly
coupled to Gi, which inhibits adenyl cyclase, or Gq,
which increases intracellular calcium. We and others
have previously shown that the inhibitory effects of
PGE2 on diverse lung fibroblast functions are primarily
mediated via ligation of the EP2 receptor, which is the
most abundantly expressed EP receptor in fibroblasts,
and increased cAMP (11, 25, 30). To determine the
receptors through which PGE2 signals to increase
DNMT3a expression, we treated cells with EP receptor-
specific ligands and observed that only the EP2 agonist
was able to increase DNMT3a mRNA (Fig. 5C). Further-
more, the direct adenyl cyclase activator forskolin also
was able to increase DNMT3a expression. Among the
two Gs-associated EP receptors, inhibition of the EP2
receptor, but not of the EP4 receptor, was able to
abrogate the effects of PGE2 on DNMT3a expression
(Fig. 5D). These findings suggest that PGE2 increases
DNMT3a expression via EP2-cAMP signaling. Fittingly,
treatment with thromboxane A2, which has been shown
to decrease cAMP levels via its Gi-coupled TP receptor,
resulted in a decrease in DNMT3a expression (Fig. 5B).
To determine whether the increase in DNMT3a
expression by PGE2 is due to increased transcription or
decreased degradation of its mRNA, we tested whether
the transcription inhibitor actinomycin D interfered
with the ability of PGE2 to promote DNMT3a mRNA
accumulation over time (Fig. 6A). Data for cells treated
with actinomycin D alone indicated that DNMT3a
mRNA degraded by 80% in 24 h. PGE2 did not
change the rate of degradation but was unable to
increase DNMT3a mRNA in the presence of actinomy-
cin D treatment. This suggests that the increase in
DNMT3a by PGE2 is due to de novo transcription.
Previous studies have shown that DNMT3a expres-
sion can be dictated by the transcription factors Sp1
and Sp3 (31). To determine whether the increase in
DNMT3a expression by PGE2 is due to up-regulation of
Sp1 and/or Sp3, we assayed the expression and activity
of these transcription factors. PGE2 increased Sp1 and
Sp3 mRNA levels (Fig. 6B) as well as nuclear Sp1 activity
(Fig. 6C) in both fetal and adult fibroblasts. The
Sp1/Sp3 inhibitor mithramycin attenuated the ability
of PGE2 to increase DNMT3a mRNA (Fig. 6D). These
data show that the PGE2-mediated increase in DNMT3a
is due, at least in part, to increased Sp1/Sp3 transcrip-
tion factor expression and activity.
PGE2 decreases DNMT expression in RAW 264.7
macrophages
To determine whether the increase in DNMT3a expres-
sion by PGE2 is specific to lung fibroblasts, we exam-
ined the expression of DNMTs in RAW 264.7 macro-
phages after treatment with PGE2. Interestingly, PGE2
decreased the expression of DNMT1 and DNMT3a in
RAW cells (Fig. 7), suggesting that the PGE2 effects on
DNA methylation machinery are cell type-specific.
DISCUSSION
Although patterns of DNA methylation are highly plas-
tic and sensitive to environmental cues (1, 2, 32), the
mechanisms by which environmental perturbations di-
rect changes in DNA methylation are not well under-
stood. Synthesized from arachidonic acid via the COX
pathway, PGE2 is produced by nearly all cells and exerts
a myriad of bioactive actions. PGE2 regulates fever,
pain, and local edema during inflammation (10); it
inhibits host defense against acute infection (14); it
promotes proliferation of epithelial cells (33); it regu-
lates T-cell differentiation (34); and it inhibits fibro-
blast functions (11, 35). Increased PGE2 promotes
carcinogenesis (33), whereas diminished PGE2 pro-
motes fibroproliferation (36), renal dysfunction (37),
and gastric cytotoxicity (38). Fundamental processes
such as differentiation, proliferation, and tumorigene-
sis are often associated with distinct changes in DNA
methylation patterns. Here we show for the first time
that exogenous PGE2 and endogenous PGE2 produc-
tion can directly increase fibroblast global and gene-
specific DNA methylation via increased DNMT3a ex-
pression and activity. PGE2 accomplishes this through
ligation of the EP2 receptor, resulting in increased
cAMP generation and increased expression of Sp1 and
Sp3, transcription factors known to increase expression
of DNMT3a. The increase in DNMT3a by PGE2 is
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specific to fibroblasts, as we found PGE2 to decrease
DNMT expression in RAW macrophages. These find-
ings provide a mechanism by which PGE2 not only is
able to modulate the expression of multiple genes but
also is able to maintain these changes over subsequent
cell divisions.
DNMT3a is generally considered a de novo DNMT,
targeting previously unmethylated CpG sites for meth-
ylation (39). It is therefore not surprising that we
observed no increase in methylation of LINE-1 or other
repeat elements, which are often considered to be
under the control of maintenance methyltransferases
such as DNMT1. Instead, we identified a specific group
of genes whose promoters exhibited increased methyl-
ation with PGE2 treatment. The identification of select
targets susceptible to hypermethylation by PGE2 is
congruent with the notion that DNMT3a exhibits gene
specificity in its methylation targets. Using an unbiased
enrichment analysis of genes identified to be hyper-
methylated by PGE2 treatment, we were able to identify
three functional clusters into which these genes can be
categorized. Two of these clusters include genes in-
volved in cell cycle and tumor suppression, in keeping
with the known ability of PGE2 to inhibit fibroblast
proliferation (11) and promote tumorigenesis (15). We
independently performed bisulfite sequencing to vali-
date hypermethylation in two of the genes identified
from these clusters, IGFBP2 and MGMT. The hyper-
methylation of MGMT was associated with a decrease in
protein expression as well as increased susceptibility to
temozolamide, a DNA-damaging agent. Another func-
tional cluster, DNA methylation, was also identified by
enrichment analysis, suggesting that PGE2 may regu-
late, by hypermethylation, other genes involved in DNA
methylation machinery. Finally, it has also been sug-
gested that DNMT3a selectively methylates imprinted
genes (40), one of which, CDKN1C, was identified in
the CpG array we performed. Identifying genes that are
hypermethylated by PGE2 may in fact aid in the discov-
ery of previously unrecognized imprinted genes.
Many of the genes that we identified to be hyper-
methylated by PGE2 in IMR-90 cells differed from those
in adult normal fibroblasts, suggesting that these tar-
gets are also cell-specific. It has been noted that cellular
expression of DNMT3a increases during embryonic
development, only to decrease to lower but still mea-
surable levels in adult cell populations (27, 39). These
differences in fetal vs. adult fibroblasts suggest that
DNMT3a may target different genes for methylation in
cells of different ages or in organs at different stages of
development. Increases in DNMT3a by PGE2 were also
noted to be specific to fibroblasts, because RAW mac-
rophages exhibited a decrease in expression of DNMT1
and DNMT3a with PGE2 treatment. Indeed, a recent
article by Xia et al. (41) reported that PGE2 increased
expression of a different set of DNMTs, DNMT1 and
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Figure 6. PGE2 regulates DNMT3a expres-
sion by enhancing Sp1 and Sp3 transcrip-
tion factor expression and activity. A)
IMR-90 cells were treated alone or in com-
bination with either PGE2 (500 nM) or with
the transcription inhibitor actinomycin D
(2.5 g/ml) for the indicated times, and
DNMT3a mRNA levels were assayed by real-
time RT-PCR. Levels of DNMT3a mRNA are
expressed relative to the no-treatment con-
trol at each time point. n  3. B) IMR-90
(left panel, n3) and adult lung fibroblasts
(right panel, n3) were treated with PGE2
(500 nM unless otherwise indicated) for 24
h, and levels of Sp1 and Sp3 mRNA were assayed by real-time RT-PCR. Levels of Sp1 and Sp3 mRNA are expressed as fold
change relative to the no-PGE2 control. C) Sp1 activity was assayed in IMR-90 and adult lung fibroblasts treated with or
without PGE2 (500 nM) for 24 h, as described in Materials and Methods. Activity values were normalized to the no-PGE2
control. n  2 for IMR-90; n  3 for adult lung fibroblasts. D) IMR-90 cells were treated for 24 h with or without PGE2 and
the Sp1/Sp3 inhibitor mithramycin at the indicated concentrations and assayed for DNMT3a mRNA levels by real-time
RT-PCR. n  3. All results are expressed as means 	 se. *P  0.05 vs. untreated. #P  0.05 for PGE2-treated cells with vs.
without 50 mM mithramycin.
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DNMT3b, in colon cancer cells. Interestingly, MGMT
was one of the genes identified to be hypermethylated
by PGE2 via DNMT3b in that study (41), suggesting that
different DNMT isoforms may also up-regulate similar
genes but in different cellular contexts.
To our knowledge, the only transcription factors
identified to regulate DNMT3a expression are Sp1 and
Sp3 (31). Here, we were able to show that PGE2, via
ligation of EP2- and Gs-dependent increases in cAMP
increased Sp1 and Sp3 expression and activity, leading
to increased DNMT3a expression. Others have shown
that PGE2, via increased cAMP production, increases
Sp1 expression and activity in other cellular contexts
(42, 43). It is likely that the time required for the
transcriptional and translational up-regulation of these
genes accounts for why the increase in global DNA
methylation by PGE2 was not observed until 48 h.
Similar increases in DNMT3a expression were observed
in cells whose PGE2 was removed after 1 h of exposure,
indicating that early signaling events were sufficient to
trigger the downstream changes in DNA methylation. It
is not surprising that the increase in DNMT3a expres-
sion was mediated by EP2 ligation and signaling, be-
cause this is the most abundant EP receptor in lung
fibroblasts (11) and has been shown to modulate most
of the other inhibitory actions by PGE2 in these cells
(11, 12, 25). The half-maximal effective concentration
of PGE2 to increase DNMT3a expression was similar to
that necessary for the inhibition of other fibroblast
functions. The ability of endogenous PGE2, via COX-2
regulation, to elicit these same effects supports the
physiological relevance of these findings. The effect of
PGE2 on DNMT3a expression may differ in other cell
types with different EP receptor profiles. Treatment
with the prostanoid thromboxane A2, which signals
through the Gi-coupled TP receptor and decreases
cAMP, resulted in decreased DNMT3a expression. The
finding that cAMP signaling leads to increased
DNMT3a expression suggests that other endogenous or
exogenous ligands that activate the cAMP pathway,
such as adenosine and -adrenergic agonists, may also
up-regulate DNMT3a expression and global DNA
methylation. In contrast and as suggested by our obser-
vations with the thromboxane agonist, mediators acting
via Gi-coupled receptors, including, for example,
chemokines, may have the opposite effect.
Although mammalian DNMT3a was first cloned and
discovered in 1998 (27), many aspects of its structure
and function remain poorly understood. Somatic point
mutations that are independently associated with a
poor outcome in acute myeloid leukemia have been
identified in DNMT3A (44). Although DNMT3a is
ubiquitously expressed in most tissues, the alternatively
spliced variant DNMT3a2 is found predominantly in
embryonic tissue (45), and it is not known how its
expression is regulated. In our experiments, DNMT3a
mRNA levels decrease by 75% by 24 h when transcrip-
tion is inhibited. There are few studies that address the
stability of DNMT3a protein, the regulation of its
subcellular localization, the mechanisms by which it
selectively targets CpG sites for methylation, or the
post-translational modifications of the enzyme. Further
studies will be required to ascertain whether PGE2
influences any of these other aspects of enzyme regu-
lation or function.
In our array analysis, setting a modest threshold of a
1.5-fold increase in methylation identified 52 genes in fetal
IMR-90 cells and 48 genes in adult cells that were hyper-
methylated by PGE2. The Illumina HumanMethylation27
array assays, on average, 1 to 2 CpG sites/gene, leavingmany
CpG sites unevaluated. Given that ELISA-based assays of
global methylation showed a 2- to 3-fold increase in methyl-
ation by PGE2, we suspect that there may be other uniden-
tified genes or chromosomal regions that are also hyper-
methylated by this prostanoid. Newer generation (e.g.,
Illumina HumanMethylation450) bead chip arrays or
other methods of genome-wide bisulfite sequencing are
required to identify other hypermethylated regions within
gene promoters or in pericentromeric heterochromatin.
In addition, we were unable to detect mRNA expression
of DNMT3L (data not shown), a catalytic enhancer of
DNMT3a (46). Enhancement of DNMT3L expression in
the presence of PGE2 up-regulation of DNMT3a expres-
sion would substantially amplify hypermethylation.
The ability of the environment to shape the DNA
methylome is well recognized, and methylation is felt to
represent a major mechanism by which environmental
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Figure 7. Effect of PGE2 on DNMT expression in RAW 264.7
macrophages. RAW 264.7 cells were treated with PGE2 (1 nM
to 10 M) for 24 h and assayed for DNMT mRNA levels by
quantitative real-time RT-PCR (n3; A) or treated for 48 h
and assayed for DNMT protein expression by immunoblot
(n2; B). Representative immunoblot is shown. Results are
expressed as means 	 se. *P  0.05 vs. untreated.
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exposures contribute to disease susceptibility (1, 47).
Diet and levels of micronutrients, such as folate, have
been shown to exert a profound effect on the methyl-
ation patterns found in mothers and their offspring (2,
32). In contrast, understanding how the methylome is
affected by environmental signals that do not affect
methyl donor levels is more challenging. Aging (48),
smoking (49), and heavy metal exposure (50) have all
been associated with changes in the DNA methylome,
and, in some cases, with changes in DNMT expression,
but the mechanisms by which these changes occur are
largely unknown. Here, we show that PGE2 can alter the
methylation landscape through direct up-regulation
and increased activity of DNMT3a. These changes have
significant clinical relevance, because PGE2 generation
is up-regulated in inflammation, infection, and cancer
and down-regulated in fibrosis. Polymorphisms in
COX-2 have been shown to modulate levels of PGE2
production (51) and diminished EP2 receptor expres-
sion, which has been observed in pulmonary fibrosis,
has been shown to impair PGE2 responsiveness (52). A
recent study showed that bisphenol A decreases PGE2
biosynthesis (53), which may therefore explain the
DNA hypomethylating effect of this environmental
toxin (32). Finally, nonsteroidal anti-inflammatory
drugs, which inhibit the catalytic activity of COX, are
over-the-counter medications used virtually indiscrimi-
nately for fever and pain. Our findings allow us to
speculate that changes in PGE2 biosynthesis or signal-
ing may contribute to alterations in DNA methylation
patterns associated with a wide variety of diseases and
environmental exposures. Moreover, the ability of
cAMP to modulate DNA methylation suggests that our
findings with PGE2 may extend to other G-protein-
coupled receptor ligands that signal by increasing or
decreasing this critical second messenger.
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